{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:39:51Z","timestamp":1790505591560,"version":"4.1.0"},"reference-count":9,"publisher":"S. Karger AG","issue":"12","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2020]]},"abstract":"<b><i>Background:<\/i><\/b> Circulating tumor cells (CTCs) have been identified and shown to have prognostic and predictive roles in several types of carcinoma. More recently, aneuploid CTCs have become subject of a growing interest, as aneuploidy is considered a hallmark of cancer often associated with poor prognosis. Here, we aimed to identify for the first time aneuploid CTCs in soft-tissue sarcoma (STS) patients and show supportive in silico evidence on the prognostic role of aneuploidy in mesenchymal cancers. <b><i>Methods:<\/i><\/b> In our pilot study, we collected blood from 4 metastatic STS patients and 4 age- and sex-matched healthy controls. After sample processing, cells were cyto-centrifuged onto glass slides and FISH was performed using 5 probes. The in silico analysis was performed using data from The Cancer Genome Atlas cohort of STS patients, using the validated Aneuploidy Score. We divided the patients in two populations (aneuploidy-high, Ane-Hi, and aneuploidy-low, Ane-Lo) using the median value of the Aneuploidy Score as a cutoff. Kaplan-Meier curves associated with log-rank test were used to compare progression-free and overall survival between groups. GraphPad Prism 8.0 (La Jolla, CA, USA) was used for statistical analyses. <b><i>Results:<\/i><\/b> Aneuploid CTCs were identified in all 4 STS patients and in none of the controls, with a median value of 4 (range 3\u20136) per 7 mL of blood. Ane-Hi patients showed a significantly worse progression-free and overall survival compared to Ane-Lo patients. The same trend was maintained when analyzing the data based on the different histologies. <b><i>Conclusions:<\/i><\/b> We identified for the first time aneuploid CTCs in STS patients using fluorescence in situ hybridization in a surface marker-independent way. We also showed that the Aneuploidy Score has a prognostic value both in terms of progression-free survival and overall survival in STS patients using The Cancer Genome Atlas data, regardless of the histology. <\/jats:p>","DOI":"10.1159\/000509326","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T21:00:33Z","timestamp":1597957233000},"page":"893-896","source":"Crossref","is-referenced-by-count":6,"title":["Identification of Aneuploid Circulating Tumor Cells in Soft-Tissue Sarcoma Patients: A Pilot Study"],"prefix":"10.1159","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7509-1555","authenticated-orcid":false,"given":"Andrea","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Minelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-019-0095-0"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/697395"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10763-7"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1538000"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13008-015-0009-7"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13591"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.538"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2174"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5850-7"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/509326","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/509326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:46:05Z","timestamp":1745423165000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000509326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":9,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,11,27]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000509326","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}